Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
9.01
-0.30 (-3.22%)
At close: Jul 31, 2026, 4:00 PM EDT
9.17
+0.16 (1.78%)
After-hours: Jul 31, 2026, 7:34 PM EDT
Kura Oncology Revenue
Kura Oncology had revenue of $18.27M in the quarter ending March 31, 2026, with 29.47% growth. This brings the company's revenue in the last twelve months to $71.64M, up 5.37% year-over-year. In the year 2025, Kura Oncology had annual revenue of $67.48M with 25.24% growth.
Revenue (ttm)
$71.64M
Revenue Growth
+5.37%
P/S Ratio
11.17
Revenue / Employee
$275,535
Employees
260
Market Cap
799.86M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 67.48M | 13.60M | 25.24% |
| Dec 31, 2024 | 53.88M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Geron | 196.12M |
| Arbutus Biopharma | 191.45M |
| Theravance Biopharma | 109.78M |
| Omeros | 9.89M |
| DBV Technologies | 5.04M |
| Odyssey Therapeutics | 1.06M |
KURA News
- 5 days ago - Kura Oncology Transcript: Study update - Transcripts
- 5 days ago - Kura Oncology Press release: Study update - Filings
- 5 days ago - Kura Oncology Slides: Study update - Filings
- 5 days ago - Kura Oncology announces durable activity of darlifarnib combination in ccRCC - TheFly
- 5 days ago - Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026 - GlobeNewsWire
- 18 days ago - Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib's Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026 - GlobeNewsWire
- 4 weeks ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Kura Oncology Transcript: Status update - Transcripts